Currently, biomarkers such as Aβ1-40, Aβ1-42, T-tau, and P-tau serve as significant foundations for the early diagnosis of Alzheimer’s disease by clinicians. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.